Maiwei Biopharmaceutical (688062.SH): Approval for clinical trial application of injectable 7MW4911 granted.

Miwe Biotechnology (688062.SH) announced that recently, the company has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The clinical trial of injectable 7MW4911 has been approved. 7MW4911 is an innovative antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17) developed based on the company's proprietary IDDC antibody conjugation technology platform. CDH17, as a potential therapeutic target validated by pan-cancer multi-omics, is limited to the expression on the basolateral membrane of intestinal epithelial cells in normal tissues, while it shows significant overexpression in gastrointestinal malignant tumors such as colorectal cancer, gastric cancer, and pancreatic cancer. Its abnormally high expression is closely related to tumor invasion, metastasis, and poor prognosis, providing an ideal target for precision intervention.